

Per Norlén to step down as Targinta CEO

Targinta announces that Per Norlén will leave his position as CEO of the company effective late January 2023 at the latest to take on the CEO role in another drug development company.

“We have started the work of recruiting a new CEO for Targinta. In the meantime, Per will continue to support Targinta’s development activities. We wish Per every success in his new position”, says Targinta's chairman Greg Batcheller.

For further information please contact:

Greg Batcheller, Chairman Targinta AB

Email: greg@xintela.se

Phone: +46 46 275 65 00

About Targinta

Targinta is a preclinical stage oncology biotech company, developing first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) for aggressive cancers based on the in-house discovery of the novel patent-protected cancer target integrin $\alpha 10\beta 1$. The pipeline includes TARG10, a function-blocking integrin $\alpha 10$ -antibody that is being developed to prevent metastasis, and TARG9, an integrin $\alpha 10$ -ADC that is armed with a powerful toxin that selectively kills tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) and is headquartered in Lund, Sweden. For more information, please visit www.targinta.se.

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

[Per Norlén to step down as Targinta CEO](#)